Combination treatment of a novel CXCR3 antagonist ACT-777991 with an anti-CD3 antibody synergistically increases persistent remission in experimental models of type 1 diabetes.

Clin Exp Immunol · 2023 · PMC10714188 · PMID 37458220

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the virus-inducible diabetes model, early discontinuation of ACT-777991 on Day 28 after infection showed a trend in improving the remission rate compared to aCD3 monotherapy, but to a lesser extent as compared to the chronic setting, suggesting the benefit of continuous blockade of the CXCR3 axis to revert diabetes.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.